Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Voyager Therapeutics (VYGR) Capital Expenditures (2016 - 2025)

Voyager Therapeutics (VYGR) has disclosed Capital Expenditures for 11 consecutive years, with $626000.0 as the latest value for Q4 2025.

  • Quarterly Capital Expenditures rose 303.87% to $626000.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $2.6 million through Dec 2025, down 26.27% year-over-year, with the annual reading at $2.6 million for FY2025, 26.27% down from the prior year.
  • Capital Expenditures hit $626000.0 in Q4 2025 for Voyager Therapeutics, up from $207000.0 in the prior quarter.
  • In the past five years, Capital Expenditures ranged from a high of $2.1 million in Q1 2024 to a low of -$1.5 million in Q4 2022.
  • Historically, Capital Expenditures has averaged $473350.0 across 5 years, with a median of $268000.0 in 2022.
  • Biggest five-year swings in Capital Expenditures: crashed 2762.07% in 2022 and later skyrocketed 1864.22% in 2024.
  • Year by year, Capital Expenditures stood at $58000.0 in 2021, then plummeted by 2762.07% to -$1.5 million in 2022, then soared by 148.9% to $755000.0 in 2023, then plummeted by 79.47% to $155000.0 in 2024, then skyrocketed by 303.87% to $626000.0 in 2025.
  • Business Quant data shows Capital Expenditures for VYGR at $626000.0 in Q4 2025, $207000.0 in Q3 2025, and $1.1 million in Q2 2025.